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Abstract: The nucleotide oligomerization domain
2 (NOD2) 3020insC (NOD2fs) mutation increases
susceptibility to Crohn’s disease (CD), but the
mechanism remains controversial. Loss-of-func-
tion and gain-of-function phenotypes have been
described as a result of NOD2fs. Here, we show
that dendritic cells (DC) derived from CD patients
homozygous for this mutation respond normally to
purified Toll-like receptor (TLR) ligands but fail to
up-regulate the costimulatory molecules CD80 and
CD86 in response to the NOD2 ligand muramyl
dipeptide (MDP). Moreover, they lack MDP-in-
duced enhancement of TLR-mediated tumor ne-
crosis factor , interleukin (IL)-12, and IL-10 pro-
duction, which is observed in control DC with in-
tact NOD2. These data indicate that the NOD2fs
mutation results in a loss-of-function phenotype in
human myeloid DC and imply decreased immune
regulation by IL-10 as a possible mechanism for
this mutation in CD. J. Leukoc. Biol. 79:
860–866; 2006.
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INTRODUCTION
Nucleotide oligomerization domain 2 (NOD2; CARD15) is
the first gene identified within the IBD1 locus, and different
NOD2 mutations are found to be associated with Crohn’s
disease (CD). Although mutations in NOD2 do not inevitably
lead to the development of CD, individuals who are homozy-
gous for the NOD2 3020insC (NOD2fs) mutation show a
dramatically (up to 38-fold) increased susceptibility [1, 2].
Thus, homozygous NOD2fs individuals constitute a unique
subset of patients to study the contribution of this mutation
to the pathogenesis of CD.
NOD2 is a cytoplasmic protein that binds muramyl dipep-
tide (MDP), a motif common to peptidoglycan of Gram and
Gram– bacteria, resulting in nuclear factor (NF)-B activation
and cytokine induction [3]. Furthermore, NOD2 activation has
been suggested to affect Toll-like receptor (TLR)-mediated
responses [4, 5].
The mechanism by which NOD2fs contributes to CD re-
mains largely unresolved. Recent data from several NOD2
mouse models have yielded surprisingly different conclusions.
TLR2-induced interleukin (IL)-12 production by myeloid cells
was found to be decreased after costimulation with MDP, an
effect absent in NOD2/ mice, implying that NOD2 is a
negative regulator of TLR2-mediated T helper cell type 1 (Th1)
responses [6]. In line with this gain-of-function phenotype of
knockout mice, NOD2fs knock-in mice showed enhanced
NF-B activity and IL-1 secretion in response to MDP as well
as increased susceptibility to bacterial-induced intestinal in-
flammation [7]. However, another mouse study demonstrated
that NOD2 activation in wild-type mice enhanced TLR-medi-
ated cytokine production by bone marrow-derived macro-
phages, and NOD2-deficient animals had decreased cryptdin
expression in terminal ileum cells and impaired antibacterial
responses after challenge with Listeria monocytogenes [8], thus
favoring a loss-of-function phenotype. Few studies have yet
focused on the effect of NOD2fs in human dendritic cells (DC),
which are the only antigen-presenting cells capable of activat-
ing naive T cells and the induction of immunity and tolerance
[9]. Also, in the gut, DC are crucial for the induction of
tolerance to the resident intestinal flora [10–12]. We therefore
aimed to determine the consequence of NOD2fs for the respon-
siveness of DC to MDP, focusing on maturation and cytokine
production. We specifically studied IL-12, tumor necrosis fac-
tor  (TNF-), and IL-10, considering their importance in
affecting inflammatory processes in general and the pathogen-
esis of CD in particular [13–16].
MATERIALS AND METHODS
Patients and genotyping of NOD2 variants
Blood was collected from 150 CD patients and 10 healthy volunteers. Poly-
merase chain reaction amplification of NOD2 gene fragments containing the
polymorphic site 3020insC was performed in 50 l reaction volumes contain-
ing 100–200 ng genomic DNA. The 3020insC polymorphism was analyzed by
Genescan analysis on an ABI PRISM 3100 genetic analyzer, according to the
protocol of the manufacturer (Applied Biosystems, Foster City, CA). Four CD
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patients were found to be homozygous for the NOD2fs mutation and were selected
for further studies. As control groups, four patients with CD bearing the wild-type
allele and five healthy volunteers homozygous for the wild-type NOD2 allele were
included. Approval from the local regulatory committee was obtained.
Isolation of mononuclear cells and generation of
monocyte-derived DC (moDC)
After informed consent, 80 ml venous blood was drawn from the cubital vein
of patients and healthy volunteers into 10 ml EDTA tubes (Monoject, s-
Hertogenbosch, The Netherlands). Total blood was diluted 1/1 using phos-
phate-buffered saline (PBS) containing 0.45% sodium citrate (dilution solu-
tion), and mononuclear cells were isolated by density gradient centrifugation
using Lymphoprep (1.077 g/ml, Axis Shield PoC AS, Oslo, Norway), according
to the manufacturer’s instructions. Cells were washed once in dilution solution
at 1800 rotations per minute (rpm) for 8 min to remove Lymphoprep remains
and further washed (1500 rpm/5 min) using ice-cold dilution solution contain-
ing 1% fetal calf serum (FCS) until clear supernatant was obtained. After
counting, cells were resuspended in RPMI containing 2% human serum (HS)
at a density of 10–12.5  106 cells/ml and plated in T25 or T75 culture flasks
(Costar, Corning, NY) at 37°C for a period of 1 h. Nonadherent cells were
removed by washing 3 with PBS, and adherent cells were cultured in RPMI
1640 supplemented with 100 U/ml antibiotic-antimycotic (Invitrogen, Carls-
bad, CA), 10 mM L-glutamine, and 10% FCS. To generate moDC, 400 U/ml
IL-4 and 800 U/ml granulocyte macrophage-colony stimulating factor (GM-
CSF; Schering-Plough, Kenilworth, NJ) were added to the culture medium,
which was refreshed, and complete cytokines were added at Day 3. On Day 6,
immature DC were harvested using cold PBS, and cells were stimulated as
indicated below. An average yield of 2.3 106 (SD 0.7106) immature DC was
obtained per donor.
Stimulation of DC
For cytokine analysis, immature moDC (50103) in 100 l medium were
added to round-bottom, 96-well plates (Costar) with 50 l culture medium
(negative control) or 50 l medium containing the various stimuli, purified
lipopolysaccharide (LPS; Escherichia coli, 100 ng/ml), synthetic Pam3 Cys-
Ser-(Lys)4 .3HCl (Pam3Cys; 10 g/ml, EMC Microcollections, Germany),
synthetic polyionisicpolycytidylic acid [poly(I:C); 20 g/ml, Sigma-Aldrich, St.
Louis, MO] in the presence or absence of MDP (5 g/ml, Sigma-Aldrich),
interferon- (IFN-; 400 U/ml), or a combination of both MDP and INF- for
a period of 24 h. For flow cytometry, immature moDC (0.6106) in a 1.5-ml vol
were added to 12-well plates (Costar) and incubated with 20 g/ml poly(I:C) or
10 g/ml Pam3Cys for a period of 24 h, after which, the expression of
costimulatory molecules was analyzed using flow cytometry.
Flow cytometric analysis of costimulatory
molecule expression on DC
After 24 h incubation with indicated TLR ligands, cells were harvested and
washed using ice-cold PBA (PBS containing bovine serum albumin and azide).
Cells (50103 cells/well) were added to a v-bottom, 96-well plate (Costar) and
stained using CD80 or CD86-specific mouse anti-human immunoglobulin G1
(IgG1) antibodies or the appropriate isotype control (BD PharMingen, San
Diego, CA) on ice for a period of 30 min. Cells were washed twice in ice-cold
PBA and incubated with phycoerythrin-labeled goat anti-mouse Ig (BD Phar-
Mingen) on ice for a period of 30 min. After double washings, cells were
incubated in 200 l PBA, and the expression of CD80 and CD86 was analyzed
via flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA). Analysis
was done using WinMDI 2.8 software.
Cytokine measurements
After 24 h stimulation, supernatants were harvested and stored at –80°C until
cytokine analysis was performed. IL-12 concentrations in supernatants were
measured using an IL-12p70-specific sandwich enzyme-linked immunosorbent
assay (Pierce-Endogen, Rockford, IL). TNF- and IL-10 levels were deter-
mined using commercially available kits (Bio-Rad Laboratories, Hercules,
CA), according to the manufacturer’s instructions. Data analysis was done with
Bio-Plex Manager software (Bio-Rad Laboratories).
Statistical analysis
Differences in the increase in mean fluorescence intensity (MFI) of CD80 and
CD86 after 24 h stimulation with TLR ligands or MDP between individuals
homozygous for NOD2fs (n	4) and those with intact NOD2 (four CD patients
and five healthy controls) were analyzed using the Student’s t-test. Stimulation
experiments for cytokine analysis were performed in duplo. Differences in
cytokine production between cells from patients homozygous for the NOD2fs
polymorphism (n	4) and cells from individuals bearing the wild-type allele (four
CD patients and five healthy controls) were analyzed using the Student’s t-test.
RESULTS
TLR activation of NOD2fs DC leads to normal
maturation and cytokine production
To determine whether the NOD2fs mutation affects TLR-mediated
DC activation, we analyzed DC maturation (a hallmark of activa-
tion) via the expression of CD80 and CD86 on moDC from healthy
controls, CD patients with intact NOD2, and CD patients homozy-
gous for NOD2fs. For patient characteristics, see Table 1. DC
were stimulated with synthetic or highly purified TLR ligands to
avoid possible effects of contamination with enterotoxins. As
shown in Figure 1A, irrespective of their NOD2 genotype, DC
stimulated with the synthetic TLR1/2 ligand Pam3Cys or TLR3
ligand poly(I:C) responded with similar up-regulation of the DC
TABLE 1. Overview of General Patient Characteristics, Relevant Clinical Information, and Prescribed Medication at the Time of Study
Donor Age Sex Disease duration (years) Fistulae Resections Medication
Healthy control 26 M * no no
Healthy control 36 F * no no
Healthy control 35 F * no no
Healthy control 36 M * no no
Crohn (NOD2 /) 56 M 28 no no #
Crohn (NOD2 /) 53 M 34 yes no †,§
Crohn (NOD2 /) 48 M 29 yes no †,§
Crohn (NOD2 /) 60 M 11 yes yes ‡
Crohn (3020insC) 61 F 27 yes yes †,#,§
Crohn (3020insC) 57 M 38 no yes #
Crohn (3020insC) 41 M 19 yes yes †
Crohn (3020insC) 54 F 36 yes yes §
None of the patients included received prednisolone during the study. Three patients (two NOD2fs CD patients and one NOD2/ CD patient) had been treated
with Infliximab, the last infusion being more then 6 months prior to study. Taking into account the half-life of 9 days, no relevant residual Infliximab activity could
be expected. †, azathioprine; ‡, 6-mercaptopurine; #, budesonide; §, mesaline.
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maturation markers CD80 and CD86. The minor differences ob-
served in absolute expression levels between different individuals
fall within the normal donor variation. We note that a similar
up-regulation of those molecules was observed when using
(healthy control) DC generated with HS instead of FCS (data not
shown). To assess cytokine responses of DC from NOD2fs patients
in response to TLR activation, we measured IL-12, TNF-, and
IL-10 after stimulation with TLR ligands in the presence or
absence of IFN-, which is known to be present in increased
amounts in the gut of CD patients and can enhance TLR and
NOD2 responses. No significant difference in cytokine induction
by LPS alone (IL12p70, P	0.31; TNF-, P	0.32; IL-10,
P	0.18) or in combination with IFN- (IL12p70, P	0.23;
TNF-, P	0.44; IL-10, P	0.16) between NOD2fs DC and con-
trol DC was observed (Fig. 1B). These findings indicate that DC
maturation and cytokine production following TLR activation are
not altered in DC from CD patients homozygous for NOD2fs.
MDP stimulation results in modest maturation
and cytokine responses in control but not
NOD2fs DC
Next, the response of DC to the NOD2 ligand MDP was
investigated. Based on initial titration experiments, a concen-
tration of 5 g/ml MDP was used. As shown in Figure 2A,
MDP treatment resulted in a weak but consistent up-regulation
of CD80 and CD86 on DC from healthy donors and CD patients
expressing wild-type NOD2. In contrast, NOD2fs DC invari-
ably failed to increase the expression of these costimulatory
molecules. Cytokine analysis further revealed that in contrast
to what is observed after TLR4 activation with LPS, no IL-12
was detected, and only weak TNF- and IL-10 responses
[mean 1.7% (0–11%) and 0.7% (0–3%) of LPS response,
respectively] were observed following MDP stimulation in a
number of control DC but not NOD2fs DC (Fig. 2B). These
results indicate that NOD2 triggering alone does not induce
significant cytokine production in DC but does result in modest
DC maturation, which is abrogated completely in DC homozy-
gous for the NOD2fs mutation.
Lack of cross-talk between NOD2 and TLR
signals in NOD2fs DC
We and others have reported recently that MDP can increase
cytokine production when combined with TLR-activating stim-
uli [5, 17]. Considering the important role of IL-12 in CD, we
first studied the release of this major Th1-driving cytokine in
DC from healthy controls after activation with purified LPS. As
Fig. 1. TLR activation is not affected in NOD2fs DC. (A) DC were generated by culturing monocytes in the presence of IL-4 and GM-CSF for a period of 6 days.
DC from healthy controls or NOD2fs patients were stimulated with synthetic TLR ligands Pam3Cys (10 g/ml) or poly(I:C; 20 g/ml) for 24 h. CD80 and CD86
expression on the cell surface was analyzed by flow cytometry. Maturation responses shown are representative of six healthy controls and four NOD2fs patients.
Medium control and indicated TLR stimulation are represented by thin and thick lines, respectively. Filled histogram indicates isotype-matched, control
monoclonal antibodies (mAb). (B) Production of IL-12, TNF-, and IL-10 by DC from healthy controls (n	5), NOD2/ CD patients (n	4), or homozygous NOD2fs
CD patients (n	4). Cells were stimulated with LPS (E. coli, 100 ng/ml) alone or LPS in combination with 400 U/ml IFN- for a period of 24 h, after which, cytokine
concentrations in culture supernatants were analyzed.
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Fig. 2. NOD2fs DC show no maturation or cytokine production after stimulation with MDP. (A) Representative examples of the expression of CD80 and
CD86 on DC from healthy controls (n	5), NOD2/ CD patients (n	4), or NOD2fs CD patients (n	4) after stimulation with 5 g/ml N-acetylmuramyl-
L-alanyl-D-isoglutamine hydrate (MDP) for a period of 24 h. Medium control and MDP stimulation are indicated by thin and thick lines, respectively. Filled
histogram represents isotype-matched, control mAb. Increase in MFI of CD80 and CD86 after MDP stimulation was calculated. Differences between DCs
from donors with intact NOD2 and NOD2fs DC were compared using Student’s t-test (*, P
0.05). (B) IL-12, TNF-, and IL-10 levels (pg/ml) in culture
supernatant, comparing stimulation of cells with 100 ng/ml-purified LPS or 5 g/ml MDP for a period of 24 h. No IL-12 could be detected after stimulation
with MDP, whereas some, but not all, control DC responded with the production of low levels of TNF- or IL-10.
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shown in Figure 3A, IL-12 was undetectable after MDP
stimulation, alone or in combination with IFN-. In contrast,
TLR4 activation using LPS resulted in an appreciable amount
of IL-12 (120 pg/ml), which was further enhanced by IFN-. In
the presence and absence of IFN-, additional stimulation with
MDP resulted in a significant increase in IL-12 as compared
with LPS or LPS/IFN- alone. Thus, the reported synergy
between TLRs and NOD2 for the production of cytokines also
applies for IL-12 release by human DC.
Next, we studied the consequences of the NOD2fs mutation
on cytokine production following combined NOD2/TLR stim-
ulation in DC. Cells were treated with LPS, Pam3Cys, or poly
Fig. 3. The NOD2fs mutation abrogates the synergy between TLR and NOD2 signals for release of cytokines. (A) IL-12 production by DC from healthy controls
was measured after stimulation with 5 g/ml MDP, 100 ng/ml purified LPS, or a combination of both in the presence or absence of 400 U/ml IFN-. Data shown
are the mean  SD of triplicate measurements of one of four independent experiments. nd, Not detectable. (B) IL-12, TNF-, and IL-10 levels were measured
following stimulation of DC from healthy controls (n	5), NOD2/ CD patients (n	4), or NOD2fs CD patients (n	4) with 100 ng purified LPS, 10 g/ml Pam3Cys
(PAM), or 20 g/ml poly(I:C), alone or in combination with 5 g/ml MDP for 24 h. Experiments were performed without (upper panel) or with (lower panel)
additional IFN- stimulation. Displayed is the percentage increase in cytokine production as a result of the addition of MDP compared with TLR stimulation alone.
Differences in the observed increases in cytokine levels between control DC and NOD2fs DC were analyzed using Student’s t-test (*, P
0.05, and **, P
0.01).
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(I:C) in the presence or absence of IFN-, with or without
additional stimulation with MDP. IL-12, TNF-, as well as
IL-10 production was measured. Results are depicted as the
percent increase in cytokine levels, comparing TLR activation
alone with TLR activation combined with MDP (Fig. 3B). In
control DC, stimulation with TLR ligands in the presence of
MDP resulted in a significant increase in IL-12, IL-10, and
TNF- levels compared with TLR activation alone, although
this effect was not significant for all cytokines measured or all
TLR ligands used. The synergistic effect of MDP stimulation
on TLR-induced cytokine release was completely absent in DC
from NODfs patients. In the presence of IFN-, there was a
statistically significant difference for all cytokines measured
after stimulation with the selected TLR ligands and MDP,
indicating that in a proinflammatory Th1 environment, the
effect of NOD2fs could become even more apparent.
Together, these results demonstrate that the 3020insC mu-
tation renders DC unable to mature in response to MDP and
abrogates the synergy between NOD2 and TLRs for the pro-
duction of pro- and anti-inflammatory cytokines.
DISCUSSION
CD is associated with high levels of the NF-B-induced cyto-
kines IL-12 and TNF-, and mAb against these cytokines are
effective therapies for CD [18–20]. It is striking that decreased
NF-B activation and defective cytokine responses have been
reported in human and mouse studies as a consequence of the
CD-associated NOD2fs mutation, providing evidence for a
loss-of-function phenotype [1, 8, 21, 22]. However, two recent
studies in mice challenged this view [6, 7]. Watanabe and
colleagues [6] suggested that NOD2 is a negative regulator of
TLR2-induced Th1 responses, as measured by IL-12 produc-
tion. Wild-type cells stimulated with the TLR2 ligand Pam3Cys
plus MDP displayed lower IL-12 production than cells from
NOD2/ mice, which were stimulated similarly [6]. In addi-
tion, Maeda et al. [7] developed a mouse model in which the
NOD2fs variant was introduced into the mouse NOD2 locus
and showed that mutant mice exhibited elevated NF- acti-
vation and IL-1 secretion following MDP stimulation, sug-
gesting that the NOD2fs mutation would lead to a gain-of-
function phenotype. This discrepancy between recent mouse
and human data published necessitates further studies in,
preferentially, human subjects. A lot of studies have used
transfected human cell lines, but in these systems, NOD2
expression is well above physiological levels with unknown
outcome. Also, the use of (patient-derived) peripheral blood
mononuclear cells (PBMC) complicates identification of the
effect of NOD2fs in specific cell types within this mixed
population.
DC are present in the intestinal mucosa, where they sense
the content of the intraluminal bacterial milieu, and they are
crucial in the decision process between tolerance and immu-
nity [12, 23]. We therefore decided to determine the conse-
quence of the NOD2fs mutation in myeloid DC obtained from
patients homozygous for this NOD2 polymorphism. Our results
indicate that intact NOD2 is essential for the recognition of
MDP by human DC and support the view that the NOD2fs
mutation in CD patients results in a loss-of-function phenotype
in these cells. To avoid the unwanted effect of possible con-
tamination with, for instance, endotoxins, we used only syn-
thetic or highly purified TLR and NOD2 ligands during our
study. DC from CD patients bearing the NOD2fs mutation
responded with a normal up-regulation of the costimulatory
molecules CD80 and CD86 after TLR activation but failed to
do so in response to MDP. The production of IL-12p70, TNF-,
and IL-10 was not significantly different between DC from
control and NOD2fs DC after TLR activation. MDP induced
low cytokine responses in some but not all DC carrying intact
NOD2, and NOD2fs DC did not produce any cytokines follow-
ing MDP stimulation alone. Finally, in control DC, stimulation
with TLR ligands plus MDP enhanced the production of IL-12,
TNF-, and IL-10 compared with those levels obtained follow-
ing TLR activation alone. This synergy between NOD2 and
TLRs was completely absent in DC obtained from patients with
the NOD2fs polymorphism. These results are in concordance
with the recent findings by van Heel et al. [22], who showed
that PBMC from homozygous NOD2fs donors display signifi-
cantly decreased TNF- and IL-1 production following com-
bined activation of TLRs and NOD2.
In the presence of IFN-, which is known to increase NOD2
and TLR expression and function [24–26], the observed dif-
ferences were even more significant. The absence of an in-
crease in IL-12 production by simultaneous TLR2 and NOD2
activation in NOD2fs DC is at variance with findings reported
in NOD2-deficient mice [6]. The reason for this discrepancy is
currently unknown but might be related to differences between
the NOD2fs mutation and complete absence of NOD2 or (spe-
cies-related) differences between human DC and mouse
splenocytes. In addition, other mutations in NOD2 might have
different consequences, for instance, in the case of Blau syn-
drome [27].
The inflammatory phenotype found in CD patients is hard to
explain by a decreased TNF- and IL-12 production by
NOD2fs DC after combined TLR/NOD2 activation. However,
we now demonstrate that NODfs DC also produce decreased
amounts of the anti-inflammatory cytokine IL-10 under these
conditions. IL-10 is crucially involved in preventing excessive
immune responses, including down-regulation of IL-12 and
TNF- production [28]. We therefore postulate that deficient
IL-10-mediated immune suppression is dominant over the
reduction in TNF- and IL-12 levels, which is also observed
after TLR/NOD2 stimulation in NOD2fs DC. As DC instruct
the adaptive immune system via the release of specific cytokine
combinations, a disturbed organization of this cytokine produc-
tion could induce unwanted T cell responses. Indeed, studies
using therapeutic IL-10 administration or IL-10-deficient mice
have demonstrated the importance of this cytokine in prevent-
ing mucosal inflammation [29, 30]. Furthermore, IL-10 is a
multifunctional cytokine that is also crucial for the develop-
ment of suppressor T cells, which are involved intricately in
controlling intestinal immune responses [31–33]. NOD2fs-re-
lated reduction in IL-10 levels could thus result in a defective
counter-regulation of the effect of proinflammatory cytokines
with concomitant Th1 responses and thereby contribute to the
perpetuation of chronic inflammation characteristic for CD.
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